BioCentury
ARTICLE | Clinical News

AVA-101: Phase IIa data

June 22, 2015 7:00 AM UTC

Top-line data from a Phase IIa trial in 32 wet AMD patients ages >=55 showed that a single sub-retinal injection of AVA-101 plus Lucentis ranibizumab on day 0 and at week 4 met the primary safety end...